Improving treatment of non-Hodgkin lymphoma (NHL) through pretargeted radioimmunotherapy (PT-RIT) and consolidation veltuzumab (humanized anti-CD20) IgG serotherapy

被引：0
|
作者：
Sharkey, R. M. [1 ,2 ]
Karacay, H. [1 ,2 ]
Johnson, C. R. [1 ,2 ]
Rossi, E. A. [3 ]
McBride, W. J. [4 ]
Chang, C-H [3 ,4 ]
Goldenberg, D. M. [1 ,2 ,3 ,4 ]
机构：
[1] Ctr Mol Med & Immunol, Belleville, NJ USA
[2] Garden State Canc Ctr, Belleville, NJ USA
[3] IBC Pharmaceut Inc, Morris Plains, NJ USA
[4] Immunomedics Inc, Morris Plains, NJ USA
来源：
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS | 2008年 / 23卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
26
引用
收藏
页码：521 / 521
页数：1
相关论文
共 50 条
  • [31] Anti-CD20 monoclonal antibodies as novel treatments for non-Hodgkin's lymphoma
    White, CA
    Larocca, A
    Grillo-López, AJ
    PHARMACEUTICAL SCIENCE & TECHNOLOGY TODAY, 1999, 2 (03): : 95 - 101
  • [32] Radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL) with IDEC-Y2B8 90yttrium anti-CD20 monoclonal antibody.
    Wiseman, G
    Witzig, T
    White, CA
    Solinger, A
    Gordon, L
    Raubitschek, A
    Emmanouilides, C
    Gutheil, J
    Parker, E
    Chinn, P
    Grillo-Lopez, A
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1998, 13 (01) : 59 - 59
  • [33] Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma
    Krasniqi, Ahmet
    D'Huyvetter, Matthias
    Xavier, Catarina
    Van der Jeught, Kevin
    Muyldermans, Serge
    Van der Heyden, Jose
    Lahoutte, Tony
    Tavernier, Jan
    Devoogdt, Nick
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (12) : 2828 - 2839
  • [34] Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma
    Protheroe, A
    Edwards, JCW
    Simmons, A
    Maclennan, K
    Selby, P
    RHEUMATOLOGY, 1999, 38 (11) : 1150 - 1152
  • [35] Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab
    Schmitz, K
    Brugger, W
    Weiss, B
    Kaiserling, E
    Kanz, L
    BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (02) : 571 - 572
  • [36] Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma
    Witzig, Thomas E.
    Tomblyn, Michael B.
    Misleh, Jamal G.
    Kio, Ebenezer A.
    Sharkey, Robert M.
    Wegener, William A.
    Goldenberg, David M.
    HAEMATOLOGICA, 2014, 99 (11) : 1738 - 1745
  • [37] I-131-LL2 (anti-CD22) radioimmunotherapy (RIT) of refractory non-Hodgkin's lymphoma (NHL): Results of a repetitive dosing trial.
    Vose, J
    Colcher, D
    Bierman, P
    Leichner, P
    Akabani, G
    Harrison, K
    Hohenstein, M
    Lesser, S
    Hammershaimb, L
    Goldenberg, DM
    Tempero, M
    Armitage, J
    JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (05) : 211 - 211
  • [38] In vitro evaluation of pretargeting system with anti-CD20 mAb for targeting non-Hodgkin's lymphoma
    Kim, H.
    Lee, I.
    Shin, E.
    Lee, E.
    Chung, H.
    Shim, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S645 - S646
  • [39] Endostatin induces tumor stabilization after chemo- or anti-CD20 therapy of high-grade non-Hodgkin's lymphoma (NHL)
    Bertolini, F
    Fusetti, L
    Mancuso, P
    Gobbi, A
    Corsini, C
    Ferrucci, PF
    Martinelli, G
    Pruneri, G
    EXPERIMENTAL HEMATOLOGY, 2000, 28 (07) : 66 - 67
  • [40] Therapy of refractory non-Hodgkin's lymphoma (NHL) with I-131-LL2 (anti-CD22) radioimmunotherapy (RIT): Results of a repetitive dosing trial.
    Vose, J
    Colcher, D
    Bierman, P
    Leichner, P
    Akabani, G
    Harrison, K
    Hohenstein, M
    Lesser, S
    Hammershaimb, L
    Goldenberg, DM
    Tempero, M
    Armitage, J
    BLOOD, 1996, 88 (10) : 2258 - 2258
12345